MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 60,602 shares, a decline of 69.4% from the November 30th total of 198,092 shares. Based on an average trading volume of 425,605 shares, the short-interest ratio is currently 0.1 days. Currently, 2.8% of the shares of the stock are short sold. Currently, 2.8% of the shares of the stock are short sold. Based on an average trading volume of 425,605 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

A number of research firms have recently commented on MTVA. HC Wainwright began coverage on shares of MetaVia in a report on Thursday, September 4th. They issued a “buy” rating and a $132.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of MetaVia in a research report on Monday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MetaVia currently has an average rating of “Hold” and a consensus target price of $82.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new stake in MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Trading Up 1.8%

NASDAQ:MTVA opened at $9.76 on Thursday. The stock’s 50-day moving average is $9.20 and its 200-day moving average is $8.67. MetaVia has a 1-year low of $6.05 and a 1-year high of $30.25. The stock has a market cap of $21.47 million, a P/E ratio of -1.17 and a beta of 0.29.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.86) by $1.32. As a group, equities analysts forecast that MetaVia will post -3.9 EPS for the current year.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.